Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy

Emerging evidence for adapting radiotherapy to immunotherapy

(2023) Lorenzo Galluzzi et al.   Nature Reviews Clinical Oncology

Immunotherapy targeting different immune compartments in combination with radiation therapy induces regression of resistant tumors

(2023) Nils-Petter Rudqvist et al.   Nature Communications

Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.

(2022) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy

(2022) Ran Salomon et al.   Frontiers in Immunology

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer

(2020) Eric X. Chen et al.   JAMA Oncology

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens

(2018) Jeremy D. Waight et al.   CANCER CELL

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE